BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26426383)

  • 1. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
    Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
    Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
    Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
    Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
    Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
    Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
    Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
    Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
    Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review.
    Daniels JA; Lederman HM; Maitra A; Montgomery EA
    Am J Surg Pathol; 2007 Dec; 31(12):1800-12. PubMed ID: 18043034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib: deaths from infections. Toxicity and doubtful efficacy.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30688423
    [No Abstract]   [Full Text] [Related]  

  • 11. Colitis due to idelalisib in a patient with follicular lymphoma.
    Canelo-Vilaseca M; Ribera Santasusana JM; Sancho Cia JM
    Med Clin (Barc); 2022 Jul; 159(2):106. PubMed ID: 35525678
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
    Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
    Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
    Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 16. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
    Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
    de Weerdt I; Koopmans SM; Kater AP; van Gelder M
    Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.